Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Folkes

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|December 13, 2002
ONT-093 (Ontogen)Prakash Mistry, Adrian Folkes
Bioorganic & Medicinal Chemistry Letters|August 6, 2002
Novel inhibitors of plasminogen activator inhibitor-1: development of new templates from diketopiperazinesShouming Wang, Julian Golec, Warren Miller, et al.
Journal of Medicinal Chemistry|March 5, 2004
Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistanceShouming Wang, Adrian Folkes, Irina Chuckowree, et al.
Journal of Medicinal Chemistry|March 5, 2004
Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistanceShouming Wang, Nan Chi Wan, John Harrison, et al.
Bioorganic & Medicinal Chemistry Letters|March 23, 2002
Design, synthesis and in vitro evaluation of potent, novel, small molecule inhibitors of plasminogen activator inhibitor-1Adrian Folkes, S David Brown, Lynne E Canne, et al.
Bioorganic & Medicinal Chemistry Letters|March 30, 2010
Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitorTimothy P Heffron, Megan Berry, Georgette Castanedo, et al.
Molecular Cancer Therapeutics|July 9, 2009
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941Florence I Raynaud, Suzanne A Eccles, Sonal Patel, et al.
Journal of Medicinal Chemistry|January 7, 2010
Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancerDaniel P Sutherlin, Deepak Sampath, Megan Berry, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Current Opinion in Investigational Drugs (London, England : 2000)|December 13, 2002
ONT-093 (Ontogen)Prakash Mistry, Adrian Folkes
Bioorganic & Medicinal Chemistry Letters|August 6, 2002
Novel inhibitors of plasminogen activator inhibitor-1: development of new templates from diketopiperazinesShouming Wang, Julian Golec, Warren Miller, et al.
Journal of Medicinal Chemistry|March 5, 2004
Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistanceShouming Wang, Adrian Folkes, Irina Chuckowree, et al.
Journal of Medicinal Chemistry|March 5, 2004
Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistanceShouming Wang, Nan Chi Wan, John Harrison, et al.
Bioorganic & Medicinal Chemistry Letters|March 23, 2002
Design, synthesis and in vitro evaluation of potent, novel, small molecule inhibitors of plasminogen activator inhibitor-1Adrian Folkes, S David Brown, Lynne E Canne, et al.
Bioorganic & Medicinal Chemistry Letters|March 30, 2010
Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitorTimothy P Heffron, Megan Berry, Georgette Castanedo, et al.
Molecular Cancer Therapeutics|July 9, 2009
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941Florence I Raynaud, Suzanne A Eccles, Sonal Patel, et al.
Journal of Medicinal Chemistry|January 7, 2010
Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancerDaniel P Sutherlin, Deepak Sampath, Megan Berry, et al.
Pageof 1